How Abpro Plans to Leverage the Public Markets

Ian Chan, CEO of Abpro, discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering. Abpro's platform can create novel antibodies at industry-leading speeds, which are then reassembled into custom configurations for therapeutic purposes. They have developed bispecific antibodies, particularly T cell engagers for oncology, which are effective against solid tumors. Abpro's lead oncology program for breast cancer, in partnership with Celltrion, is advancing through clinical phases. Additionally, they have an eye care molecule targeting AMD and DME. The recent NASDAQ listing will aid in accelerating R&D and commercialization efforts. Collaborations, like the one with Celltrion, have been instrumental in the company's success.

Given the recent NASDAQ listing, how does Abpro plan to leverage the public markets to accelerate R&D, and commercialization efforts?

That was actually, I would say, a good step forward for the company. I know last year was an exceptionally difficult year for many biotechs to go public, so that took quite a bit of work from our entire team, and we're happy that we were able to successfully accomplish that. And I think there were less than 25 companies that went that route last year. I think it gives us a great platform to grow from. We have a very supportive existing set of investors, as well as strategic partners like salt that really, I mean, they're essentially helping us fund the entire LEAD program, which really reduces the cash burden on a company. At the same time, we have the access to the public markets, there are a lot more different types of financing instruments that are available, which are now available to the company as we seek to advance other programs in addition to that. We're looking forward to it, so that it's going to be great to have the resources to pursue more programs that ultimately benefit patients.